Jordan Fenlon

Jordan Fenlon

Auto-generated profile, based on publicly available information

Jordan Fenlon

Department of Radiation Oncology, Huntsman Cancer Institute – University of Utah, Salt Lake City, Utah

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2022 in International Journal of Gynecological Cancer
Verified
Journal Article
Closed access
PDF file
JFJordan B Fenlon
Jordan B Fenlon
ARAnne F Rositch
Anne F Rositch
BDBrittney L Dickey
Brittney L Dickey
SKStephen Kimani
Stephen Kimani
GSGita Suneja
Gita Suneja
Appropriate diagnosis and treatment of gynecological cancers in people living with human immunodeficiency virus (HIV) remains a clinical challenge given rapid changes in both HIV and cancer management and a lack of prospective clinical trial data inclusive of the HIV population. A semi-systematic literature review was performed to identify published studies addressing risk factors, screening, treatment efficacy, treatment toxicity, and prognosis for people living with HIV diagnosed with gynecological malignancies, with a focus on radiotherapy and cervical cancer, given the relative paucity of literature on uterine, ovarian, and vulvovaginal cancers in people living with HIV. People living with HIV are more likely to be co-infected with human papilloma virus and more likely to develop human papilloma virus-associated malignancies. People living with HIV are less likely to receive cancer treatment compared with HIV-uninfected cancer patients, even after adjusting for differences in clinical features and sociodemographic variables. The literature on cervical cancer outcomes is mixed, with some studies demonstrating that people living with HIV have inferior treatment tolerability, response rates, and survival following chemoradiotherapy, and others showing no difference in these outcomes, particularly in patients receiving antiretroviral therapy. Importantly, even in the series showing inferior outcomes in people living with HIV, there were long-term survivors after administration of curative therapy. Consistent with published cancer management guidelines, people living with HIV diagnosed with gynecological cancers should be treated with standard cancer therapy. Co-management with the patient’s HIV specialist is critical to avoid overlapping toxicities and provide optimal supportive care. The morbidity and mortality caused by gynecologic cancers in this population can be mitigated by early diagnosis, appropriate treatment delivery including inclusion of people with HIV in cancer clinical trials, and diligent HIV management.

20 December 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
JFJordan B. Fenlon
Jordan B. Fenlon
RHRyan J. Hutten
Ryan J. Hutten
CWChristopher R. Weil
Christopher R. Weil
SLShane Lloyd
Shane Lloyd
DCDonald M. Cannon
Donald M. Cannon
YHYing J. Hitchcock
Ying J. Hitchcock

3 August 2023 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
JFJordan B. Fenlon
Jordan B. Fenlon
GNGeoff Nelson
Geoff Nelson
KTKathlina M. Teague
Kathlina M. Teague
SCSavannah Coleman
Savannah Coleman
DSDennis Shrieve
Dennis Shrieve
JTJonathan Tward
Jonathan Tward

13 August 2022 in Brachytherapy
Verified
Journal Article
Closed access
RHRyan J. Hutten
Ryan J. Hutten
JFJordan B. Fenlon
Jordan B. Fenlon
AKAdam C. Kessel
Adam C. Kessel
KSKrystal M. Straessler
Krystal M. Straessler
YHY. Jessica Huang
Y. Jessica Huang
LBLindsay M. Burt
Lindsay M. Burt

21 November 2022 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JFJordan B. Fenlon
Jordan B. Fenlon
RHRyan J. Hutten
Ryan J. Hutten
SJSkyler B. Johnson
Skyler B. Johnson
BHBoyu Hu
Boyu Hu
HSHarsh Shah
Harsh Shah
RTRanda Tao
Randa Tao
Radiotherapy (RT) utilization for early-stage, low-grade follicular lymphoma (FL) is low despite treatment guideline recommendations. We compare treatment trends for early-stage FL in the era of involved-site RT and rituximab. We identified 11,645 patients in the National Cancer Database (NCDB) with stage I–II, grade 1–2 nodal or extranodal FL diagnosed 2011–2017, with median follow-up of 44 months. From 2011 to 2017, RT utilization rates decreased from 33.4% to 22.4%, observation decreased from 65.3% to 49.7%, chemoimmunotherapy increased from 0.5% to 15.0%, immuno-monotherapy increased from 0.6% to 10.2%, and RT + systemic therapy increased from 0.6% to 2.5%. RT utilization remains low in the involved-site RT and rituximab era.

4 April 2025 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
JFJordan Fenlon
Jordan Fenlon
NBNathan Van Bibber
Nathan Van Bibber
JMJonathon Mahlow
Jonathon Mahlow
KYKosj Yamoah
Kosj Yamoah
ASAlex C Soupir
Alex C Soupir
ACAnna Elizabeth Coghill
Anna Elizabeth Coghill
Background: Cancer outcomes in people living with human immunodeficiency virus (PWH) may be driven in part by a distinct tumor microenvironment (TME) for cancers that develop in the setting of persistent immune dysfunction. Methods: Tumor samples from PWH were retrospectively obtained from the AIDS Cancer Specimen Resource, Moffitt Cancer Center, and Huntsman Cancer Institute. Staining of 22 different tumor immune markers was compared between PWH and cancer and patients diagnosed with the same cancer type but without human immunodeficiency virus. Results: A total of 292 samples were analyzed, with 51 samples obtained from PWH (lung cancer = 17; breast cancer = 14; and prostate cancer = 20). Cells positive for PD-1 were observed more frequently in PWH and lung cancer [OR, 1.88; 95% confidence interval (CI), 1.02–3.45], whereas CD11b+ cells were observed less frequently (OR, 0.4; 95% CI, 0.17–0.93). Three immune markers showed higher abundance in PWH and breast cancer, including PD-L1 (OR, 3.24; 95% CI, 1.52–6.91), CD14 (OR, 3.37; 95% CI, 1.14–10.0), and FOXP3 (OR, 1.91; 95% CI, 1.03–3.53). In PWH and prostate cancer, the abundance of five immune markers was higher, including PD-L1 (OR, 5.94; 95% CI, 3.77–9.34), whereas three markers had lower abundance including CD14 (OR, 0.40; 95% CI, 0.22–0.74), as well as CD16 and CD11c. Conclusions: This pilot study showed that differences in the TME exist for PWH diagnosed with age-related non-AIDS–defining cancers. Future work evaluating TME differences in relation to clinical endpoints is needed. Impact: Findings are consistent with the hypothesis of altered tumorigenesis for cancers developing in an environment of immunosuppression.